Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer
Prostate cancer (PCa) is the second-most commonly diagnosed cancer in men around the world. It is treated using a risk stratification approach in accordance with the National Comprehensive Cancer Network (NCCN) in the United States. The main treatment options for early PCa include external beam radi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/5/1621 |
| _version_ | 1797615607381753856 |
|---|---|
| author | Samantha Gogola Michael Rejzer Hisham F. Bahmad Ferial Alloush Yumna Omarzai Robert Poppiti |
| author_facet | Samantha Gogola Michael Rejzer Hisham F. Bahmad Ferial Alloush Yumna Omarzai Robert Poppiti |
| author_sort | Samantha Gogola |
| collection | DOAJ |
| description | Prostate cancer (PCa) is the second-most commonly diagnosed cancer in men around the world. It is treated using a risk stratification approach in accordance with the National Comprehensive Cancer Network (NCCN) in the United States. The main treatment options for early PCa include external beam radiation therapy (EBRT), brachytherapy, radical prostatectomy, active surveillance, or a combination approach. In those with advanced disease, androgen deprivation therapy (ADT) is considered as a first-line therapy. However, the majority of cases eventually progress while receiving ADT, leading to castration-resistant prostate cancer (CRPC). The near inevitable progression to CRPC has spurred the recent development of many novel medical treatments using targeted therapies. In this review, we outline the current landscape of stem-cell-targeted therapies for PCa, summarize their mechanisms of action, and discuss avenues of future development. |
| first_indexed | 2024-03-11T07:29:05Z |
| format | Article |
| id | doaj.art-bb4310479b3e4dfb9193d5db2a8edb1e |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T07:29:05Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-bb4310479b3e4dfb9193d5db2a8edb1e2023-11-17T07:26:33ZengMDPI AGCancers2072-66942023-03-01155162110.3390/cancers15051621Anti-Cancer Stem-Cell-Targeted Therapies in Prostate CancerSamantha Gogola0Michael Rejzer1Hisham F. Bahmad2Ferial Alloush3Yumna Omarzai4Robert Poppiti5Department of Translational Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USADepartment of Translational Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USAThe Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USAThe Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USADepartment of Translational Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USADepartment of Translational Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USAProstate cancer (PCa) is the second-most commonly diagnosed cancer in men around the world. It is treated using a risk stratification approach in accordance with the National Comprehensive Cancer Network (NCCN) in the United States. The main treatment options for early PCa include external beam radiation therapy (EBRT), brachytherapy, radical prostatectomy, active surveillance, or a combination approach. In those with advanced disease, androgen deprivation therapy (ADT) is considered as a first-line therapy. However, the majority of cases eventually progress while receiving ADT, leading to castration-resistant prostate cancer (CRPC). The near inevitable progression to CRPC has spurred the recent development of many novel medical treatments using targeted therapies. In this review, we outline the current landscape of stem-cell-targeted therapies for PCa, summarize their mechanisms of action, and discuss avenues of future development.https://www.mdpi.com/2072-6694/15/5/1621prostate cancertherapy resistancecancer stem cellstargeted therapy |
| spellingShingle | Samantha Gogola Michael Rejzer Hisham F. Bahmad Ferial Alloush Yumna Omarzai Robert Poppiti Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer Cancers prostate cancer therapy resistance cancer stem cells targeted therapy |
| title | Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer |
| title_full | Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer |
| title_fullStr | Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer |
| title_full_unstemmed | Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer |
| title_short | Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer |
| title_sort | anti cancer stem cell targeted therapies in prostate cancer |
| topic | prostate cancer therapy resistance cancer stem cells targeted therapy |
| url | https://www.mdpi.com/2072-6694/15/5/1621 |
| work_keys_str_mv | AT samanthagogola anticancerstemcelltargetedtherapiesinprostatecancer AT michaelrejzer anticancerstemcelltargetedtherapiesinprostatecancer AT hishamfbahmad anticancerstemcelltargetedtherapiesinprostatecancer AT ferialalloush anticancerstemcelltargetedtherapiesinprostatecancer AT yumnaomarzai anticancerstemcelltargetedtherapiesinprostatecancer AT robertpoppiti anticancerstemcelltargetedtherapiesinprostatecancer |